# Lyfegen

> Lyfegen is a Swiss health-tech company that builds software to manage value-based drug pricing and rebate agreements. Its platform helps health insurers, governments, hospital payers, pharmaceutical firms and medical device makers automate complex rebate contracts, run pricing simulations and tap the world's largest library of value-based agreements - reducing administrative burden while helping patients access innovative therapies.

- **Founded:** 2018
- **Headquarters:** Basel, Switzerland
- **Founders:** Girisha Fernando (CEO & Founder), Michel Mohler (CFO & Co-Founder), Nico Mros (CXO & Co-Founder)
- **Team size:** 65 employees (approx.), ~15 nationalities
- **Products:** Rebate Analytics Platform (ARA), Rebate Management as a Service (RMAS), Drug Contracting Simulator, Agreements Library, Retrospective Analysis (RETRO)
- **Notable:** Built the world's largest digital repository of value-based drug pricing agreements (7,000+ public agreements)., Platform tracks over $1B in pharmaceutical revenue and manages over $0.5B in rebates annually., Claims to identify up to 30% of missed rebates and cut cross-functional admin costs by up to 97%.

## Products & services

- **Rebate Analytics Platform (ARA)** — A secure digital repository that consolidates agreements, claims and invoices, automatically assessing claims for validity and accuracy against 4,500+ drug contracting agreements covering 20 pricing models.
- **Rebate Management as a Service (RMAS)** — An end-to-end managed service that tracks rebate agreements and identifies, calculates and collects rebates on a client's behalf, said to surface up to 30% of missed rebates.
- **Drug Contracting Simulator** — Lets payers and pharma simulate complex drug pricing scenarios in real time - modeling pack detail, settlement terms, adherence, tax and more - to compare models and build business cases before signing.
- **Agreements Library** — The world's largest digital repository of value-based and public drug pricing agreements - 7,000+ agreements spanning 33 countries, 550+ drugs and 150+ manufacturers - used for benchmarking.
- **Retrospective Analysis (RETRO)** — A payer-facing analytics tool for retrospectively assessing historical rebate and contract performance.
- **LyfegenGPT** — An AI assistant that helps users navigate agreements, pricing models and platform data.

## Achievements

- Built the world's largest digital repository of value-based drug pricing agreements (7,000+ public agreements).
- Platform tracks over $1B in pharmaceutical revenue and manages over $0.5B in rebates annually.
- Claims to identify up to 30% of missed rebates and cut cross-functional admin costs by up to 97%.
- Awarded the Venture Leaders Technology certificate for high impact in healthtech.
- Raised over $22M total across seed and Series A rounds.
- Onboarded global pharma and payers including Johnson & Johnson, Pfizer and Sympany.

## Latest updates

- **2024-12** — Closed an additional CHF 5M Series A round led by TX Ventures, with aMoon participating, to scale the rebate management platform globally.
- **2024** — Expanded customer base to 50+ healthcare organizations across 8 markets in Europe, North America and the Middle East.
- **2023** — Grew the Agreements Library past 7,000 public drug pricing agreements and launched AI features including LyfegenGPT.

## Links

- Website: https://lyfegen.com
- LinkedIn: https://www.linkedin.com/company/lyfegen
- Twitter/X: https://twitter.com/lyfegenhealth
- Facebook: https://facebook.com/lyfegen

---

Profile page: https://yespress.io/lyfegen
Published by YesPress — https://yespress.io
Last updated: 2026-07-19